Gabapentin Dosing for Facial Post-Herpetic Neuralgia
Start gabapentin at 100-300 mg at bedtime or 100-300 mg three times daily, then increase by 100-300 mg every 1-7 days as tolerated until reaching 1800 mg/day (600 mg three times daily), with a maximum dose of 3600 mg/day in three divided doses if needed. 1, 2
Initial Dosing Strategy
The FDA-approved regimen for post-herpetic neuralgia (PHN) provides a rapid titration option 2:
- Day 1: 300 mg once daily
- Day 2: 600 mg/day (300 mg twice daily)
- Day 3: 900 mg/day (300 mg three times daily)
- Continue titrating to 1800 mg/day (600 mg three times daily) as the target therapeutic dose
However, the guideline-based approach allows more flexibility with slower titration (100-300 mg increases every 1-7 days) to minimize side effects, particularly in elderly patients who commonly develop PHN 1.
Target and Maximum Doses
- Effective therapeutic range: 1800-3600 mg/day in three divided doses 1, 2
- Optimal dose: 1800 mg/day (600 mg three times daily) is the primary target, as clinical studies showed comparable efficacy across the dose range 2
- Maximum dose: 3600 mg/day (1200 mg three times daily), though doses above 1800 mg/day did not demonstrate consistent additional benefit 1, 2
- Maximum interval between doses: Do not exceed 12 hours 2
Duration of Adequate Trial
An adequate trial requires 3-8 weeks for titration plus 2 weeks at maximum tolerated dose 1. This means gabapentin may require up to 2 months or more before determining efficacy 1. Pain reduction typically begins by week 1 and is maintained throughout treatment 2.
Critical Dosing Considerations
Renal Impairment
Mandatory dose adjustment is required for renal dysfunction 1, 2:
- CrCl ≥60 mL/min: 900-3600 mg/day in three divided doses
- CrCl 30-59 mL/min: 400-1400 mg/day in two divided doses
- CrCl 15-29 mL/min: 200-700 mg/day once daily
- CrCl <15 mL/min: 100-300 mg/day once daily
- Hemodialysis patients: Maintenance dose based on CrCl plus supplemental post-dialysis dose (125-350 mg after each 4-hour session) 2
Elderly Patients
Use lower starting doses and slower titration in geriatric patients, who represent the majority of PHN cases 1. Carefully assess renal function using Cockcroft-Gault equation, as elderly patients are more likely to have decreased creatinine clearance 2.
Common Pitfalls to Avoid
Nonlinear pharmacokinetics: Gabapentin has saturable absorption, requiring careful dose titration rather than simple dose increases 1
Premature discontinuation: The most common adverse events (dizziness 28%, somnolence 21%) occur primarily during titration 2, 3. Starting low and titrating slowly reduces these dose-limiting effects 1
Inadequate trial duration: Do not abandon therapy before completing at least 6-8 weeks at therapeutic doses 1
Driving impairment: Warn patients not to drive or operate complex machinery until they assess their response, as gabapentin causes significant driving impairment independent of somnolence 2
Abrupt discontinuation: Taper gradually to avoid withdrawal-precipitated seizures, even in non-epileptic patients 2
Evidence Quality
Meta-analysis of six RCTs demonstrated that gabapentin 1800 mg/day significantly reduced 24-hour average pain scores (SMD -0.50), improved sleep interference, and achieved 50% pain reduction in more patients compared to placebo 4. The 3600 mg/day dose showed greater pain reduction (SMD -0.86) but with increased adverse events 5. Research confirms efficacy is established across 1800-3600 mg/day range, with 1800 mg/day offering the best balance of efficacy and tolerability 2, 3.